Literature DB >> 2451575

Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro.

M Gschwendt1, G Fürstenberger, S Rose-John, M Rogers, W Kittstein, G R Pettit, C L Herald, F Marks.   

Abstract

The macrocyclic lactone bryostatin 1 activates protein kinase C as effectively as the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA). Nevertheless, there are only certain TPA-effects that can be induced by bryostatin 1. These include stimulation of epidermal DNA synthesis and alkaline phosphatase activity in vivo as well as activation of the Ca2+-independent, phospholipid-requiring phosphorylation of an epidermal protein in a cell-free system. Various other TPA-effects in vivo and in vitro, which are not mimicked by bryostatin 1 can be inhibited by applying bryostatin 1 30 min prior to TPA. TPA-effects suppressible by bryostatin 1 include the Ca2+-dependent stimulation of arachidonic acid and prostaglandin E2 release, of ornithine decarboxylase (ODC) activity and ODC-mRNA expression and of transglutaminase activity in keratinocytes in vivo and/or in vitro and, in addition, Epstein-Barr virus induction in Raji cells. The same is true for the conversion step (first stage of promotion) of multistage carcinogenesis. In contrast to the TPA induction of arachidonic acid and prostaglandin E2 release and of transglutaminase activity, induction by the Ca2+-ionophore and by high Ca2+-shift, respectively, are not significantly inhibited by bryostatin 1. We suggest that bryostatin 1 might inhibit a specific 'Ca2+-component' of TPA action.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451575     DOI: 10.1093/carcin/9.4.555

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

1.  A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.

Authors:  Jaffer A Ajani; Yixing Jiang; Josephine Faust; Baochong B Chang; Linus Ho; James C Yao; Steven Rousey; Shaker Dakhil; Richard C Cherny; Catherine Craig; Archie Bleyer
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

2.  Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.

Authors:  K G Steube; D Grunicke; H G Drexler
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.

Authors:  P A Wender; J DeBrabander; P G Harran; J M Jimenez; M F Koehler; B Lippa; C M Park; C Siedenbiedel; G R Pettit
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

4.  Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.

Authors:  Anna C Pavlick; Jennifer Wu; John Roberts; Mark A Rosenthal; Anne Hamilton; Scott Wadler; Kathleen Farrell; Michelle Carr; David Fry; Anthony J Murgo; Ruth Oratz; Howard Hochster; Leonard Liebes; Franco Muggia
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

5.  Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.

Authors:  J P Stewart; A T McGown; J Prendiville; G R Pettit; B W Fox; J R Arrand
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Coordinate changes in gene expression which mark the spinous to granular cell transition in epidermis are regulated by protein kinase C.

Authors:  A A Dlugosz; S H Yuspa
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

7.  A phase II study of bryostatin 1 in metastatic malignant melanoma.

Authors:  D J Propper; V Macaulay; K J O'Byrne; J P Braybrooke; S M Wilner; T S Ganesan; D C Talbot; A L Harris
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

8.  The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.

Authors:  Ayaka Washizaki; Megumi Murata; Yohei Seki; Masayuki Kikumori; Yinpui Tang; Weikeat Tan; Nadita P Wardani; Kazuhiro Irie; Hirofumi Akari
Journal:  Viruses       Date:  2021-10-09       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.